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SUMMARY
HIV+ patients often develop alterations of the plasma lipids that may implicate in development of premature coronary artery
disease. High-density lipoprotein (HDL) has an important role in preventing atherogenesis and the aim of this study was to
investigate aspects of HDL function in HIV+ patients. HIV+ patients (n = 48) and healthy control subjects (n = 45) of both sexes
with similar age were studied. Twenty-five were not being treated with antiretroviral agents, 13 were under reverse transcriptase
inhibitor nucleosidic and non-nucleosidic (NRTI+NNRTI) and 10 were under NRTI + protease inhibitors (NRTI+PI) treatment.
Paraoxonase 1 (PON1) activity and the transfer of free and esterified cholesterol, tryglicerides and phospholipids from a lipidic
nanoemulsion to HDL were analyzed. In comparison with healthy controls, HIV+ patients presented low PON-1 activity and
diminished transfer of free cholesterol and tryglicerides. In contrast, phospholipid transfer was increased in those patients, whereas
the transfer of cholesteryl esters was unchanged. NRTI+NNRTI increases the transfer of cholesteryl esters and triglycerides but in
NRTI+PI there was no difference in respect to non-treated HIV+ patients. HDL from HIV+ patients has smaller antioxidant properties,
as shown by lower PON-1 activity, and the transfer of lipids to this lipoprotein fraction is also altered, suggesting that HDL
function is defective in those patients.
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INTRODUCTION
In HIV+ and AIDS patients, dyslipidemias, including low levels of
high-density lipoprotein (HDL) cholesterol, are often found. As the
survival of those subjects is being increasingly prolonged by treatment,
they are exposed to those important risk factors for coronary artery
disease (CAD)13. Indeed, it has been described that in HIV+ patients
the incidence of premature CAD increases. It has been reported that
not only the HIV infection but also the antiretroviral treatment,
especially with protease inhibitors, elicits dyslipidemias1,6,8,14.
HDL cholesterol levels in the plasma inversely correlate with the
risk of developing CAD. HDL has several actions that are associated
with the atheroprotection such as the role in cholesterol esterification
and in the reverse cholesterol transport that promotes the removal of
the sterol from the body tissues to the liver for elimination in the
bile2,15,23. Furthermore, HDL has antioxidant properties that are mediated
mainly by paraoxonase 1 (PON1) action. This enzyme is predominantly
associated with the HDL fraction and catalyzes the degradation of
oxidized LDL phospholipids18. Other actions of HDL are the
antiadhesive, anti-inflammatory and improvement of the vascular
reactivity2,3.
In infection status HDL cholesterol levels are often decreased but
the causes of this reduction are unknown. It had been previously found
that HIV nef, a protein that enhances HIV replication and infectivity
specifically inhibits the ABCA1 dependent cholesterol efflux and apo
A1 lipidation that is linked with HDL production and role in reverse
cholesterol transport. Inhibition of the ABCA1 protein complex leads
to low HDL cholesterol levels7,22. HDL may play a role in defense
against infection and immunity29.
HDL is constantly being remodeled and lipid transfers are essential
for its role in the reverse cholesterol transport and in the esterification
of cholesterol. Both processes are intertwined and are key for the
cholesterol homeostasis in the organism28. Lipid transfers between
lipoprotein classes are bidirectional and depend on the structure and
concentration in the plasma of the donor and the acceptor lipoprotein,
as well as the action of the transfer proteins, namely cholesteryl ester
transfer protein (CETP) and phospholipid transfer protein (PLTP)16.
Due to the fact that HDL is active in many antiatherogenic processes it
has been recognized the importance of the systematic evaluation of
the functional aspects of the lipoprotein, beyond the simple
measurement of HDL cholesterol. In this study, the ability of HDL
from HIV+ patients to receive lipids such as free cholesterol (FC),
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cholesteryl esters (CE), phospholipids (PL), and triglycerides (TG) as
well as the PON1 activity were approached in HIV+ patients under
different treatment regimens and in patients that were not being treated
for the disease.
MATERIALS AND METHODS
Study population: Forty-eight HIV+ patients of both sexes and
without diagnosed co-infections as hepatitis-B (HBV) and hepatitis-C
(HCV) were studied and compared with 45 HIV serum negative healthy
control subjects of similar age range and with total plasma cholesterol
< 240 mg/dL and triglycerides < 200 mg/dL27.
Exclusion criteria were history of diabetes mellitus or previous
treatment with antidiabetic agents, hypocholesteremic agents, anti-
hypertensive medications and antioxidants; reported use of testosterone,
estrogen, growth hormone, or other steroids in the past six months.
Women using oral contraceptives were also excluded.
 Their physical characteristics and laboratorial data are shown in
Table 1. The group of HIV+ patients was further separated in three
distinct subgroups:
1) Non-treated, patients without antiretroviral treatment.
2) NRTI+NNRTI, patients who were being treated with nucleosidic
reverse transcriptase inhibitors (NRTI) and non-nucleosidic reverse
transcriptase inhibitors (NNRTI) (efavirenz, lamivudine, nevirapine,
stavudine or zidovudine).
3) NRTI+PI, patients that were being treated with both nucleosidic
reverse transcriptase inhibitors and protease inhibitors (PI) (atazanavir,
lopinavir, nelfinavir, ritonavir or saquinavir).
Groups NRTI+NNRTI and NRTI+PI were being treated for at least
the last six months. All the participants provided fully informed consent
to participate in the study that was approved by the Ethics Committee
of the Medical School Hospital of the Federal University of Santa
Catarina.
Blood biochemical analysis: Blood samples were collected after
a 12 hour fast and alcohol abstinence. Plasma total cholesterol (CHOD-
PAP; Roche, Basel, SUI), triacylglycerols (Triglyceride Rapid; Roche,
Basel, SUI) and glucose (Dimension® clinical chemistry system, Dade
Behring Inc., Newark, USA) were determined by commercial enzymatic
methods using a Cobas Mira analyzer (Roche). HDL cholesterol (HDL-
C) was measured after precipitation of the very low density lipoproteins
(VLDL) and LDL with HDL Reagent ROCHE (method
phosphotungsten acid: MgCl2) with automatic equipment. LDL-C was
estimated by the Friedewald formula12.
HIV virus load was determined by use of the Nuclisens HIV-1 QT
test (Organon Teknika BV, Boxtel, Netherland) by methodology Nucleic
Acid Sequence-based Amplification. CD4+, T cell and CD8+ T cell
counts were determined by FACscan flow cytometry (Becton Dickinson,
San Jose, CA), utilizing the assembly reactivate with monoclonal
antibodies anti CD4/CD3 and anti CD8/CD3 (Becton Dickinson, San
Jose, CA).
Paraoxonase (PON1) activity: PON1 activity was measured by
adding serum to 1 mL Tris-HCl buffer (100 mmol/L, pH 8.0) containing
2 mmol/L CaCl2 and 5.5 mmol/L paraoxon (Sigma Chemical Company,
London, Eng). The generation of p-nitrophenol was measured at 405
nm, at 37 °C in a microplate reader (Bio-Rad, Benchmark, JPN)17.
Lipid transfer from a donor artificial nanoemulsion to HDL:
The preparation of the nanoemulsion from a lipid mixture by prolonged
ultrasonic irradiation followed by ultracentrifugation was performed
as described elsewhere21.
Radioactive lipids were purchased from Amersham International
(Amersham, Little Chalfont, Buckinghanshier, UK) and were added
to the lipid mixtures. Two sets of nanoemulsions were prepared, one
labeled with 3H-cholesteryl oleate and 14C-phosphatidylcholine and the
other with 3H-triolein and 14C-cholesterol.
The assay consisted in the incubation of the radioactively labeled
nanoemulsion with whole plasma followed by chemical precipitation
of the apo B containing lipoproteins and the nanoemulsion. Finally,
the radioactive counting for the lipids that shifted from the
nanoemulsion to HDL was performed in a Packard 1600 TR model
Liquid Scintillation Analyzer (California, USA) by addition of a
scintillation solution (Packard BioScience, Groeningen, NED) to the
HDL-containing supernatant.
To assay for the transfer of the nanoemulsion radioactive lipids to
HDL, blood samples were collected from the subjects into 0.15% Na2
EDTA containing glass tubes and plasma was obtained by 15 min
centrifugation at 2,500 rpm at 4 °C. Test tubes with the plasma samples
(0.2 mL) and 0.05 mL nanoemulsion labeled with 3H-cholesteryl oleate
and 14C-phosphatidylcholine or with 3H-triolein and 14C-cholesterol were
placed in a shaking bath and incubated for 60 min at 37 °C. Then,
0.250 mL solution with 0.02% dextran sulfate (50,000 M.W.) and 0.3
mol/L MgCl2 was added to the tubes and vortexed by 30 s. Samples
were centrifuged at 3,000 rpm for 10 min and 0.250 mL of the obtained
supernatant containing the HDL plasma fraction were transferred to
vials with scintillation solution (Packard BioScience, Groeningen,
NED), vigorously shaken and left to stand for at least 45 min.
Radioactivity was determined in a Packard 1600 TR model Liquid
Scintillation Analyzer (California, USA). HDL acceptance of the
nanoemulsion lipids was calculated as the % of a given labeled lipid in
the nanoemulsion found in the HDL plasma fraction after the 60 min
incubation period.
Statistical analyses: Comparison of all data was performed using
the GraphPad Prism for Windows software (GraphPad, San Diego, CA).
The comparison between the data from HIV+ patients and control
subjects was performed by unpaired Student’s t-test and the data of
the three HIV+ subgroups were analyzed by Kruskal-Wallis
nonparametric ANOVA test. Differences were considered significant
when p value < 0.05. All data were expressed as mean ± standard
deviation (SD).
RESULTS
Table 1 shows that the Body Mass Index (BMI) of the HIV+ patients
was smaller than that of the control subjects. Regarding the plasma
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lipids, the total and LDL cholesterol as well as the triglyceride values
of the HIV+ patients were smaller than those of the controls.
HDL cholesterol did not differ between the two groups. Table 1
also shows that PON 1 activity was smaller in HIV+ than in controls.
Figure 1 shows the percentage of labeled lipids that was transferred
from the nanoemulsion to HDL. HIV+ patients show an increase in the
transfer of PL when compared control subjects (23.4 ± 1.6% and 17.5
± 0.9, respectively), whereas the transfer of FC and TG in HIV+ patients
was smaller (6.3 ± 1.1 vs. 5.0 ± 1.1% and 3.5 ± 0.6 vs. 2.7 ± 0.7%,
respectively). On the other hand, no difference in CE transfer was
observed between cases and controls.
Table 2 shows comparisons among the subgroups of HIV+ patients.
HDL-cholesterol was greater in the NRTI+NNRTI than in non-treated
and NRTI+PI subgroups and also greater than in the control HIV
negative subjects. However, LDL cholesterol, triglycerides and PON1
were similar among the three subgroups of HIV+ patients. Regarding
the data on lipid transfer to HDL, the PL and FC transfer were not
Table 2
BMI, glucose, blood lipids, PON1 activity and transfer of triglycerides (TG), free cholesterol (FC), cholesteryl esters (CE) and phospholipids (PL) from the lipidic
nanoemulsion to the HDL fraction in patients without antiretroviral therapy (non-treated), with nucleosidic reverse transcriptase inhibitors (NRTI) and non-
nucleosidic reverse transcriptase inhibitors (NNRTI) or with protease inhibitors (PI)
Parameters Non-treated NRTI with NNRTI NRTI with PI
n = 25 n = 13 n = 10
BMI (kg/m²) 23.3 ± 3.5 22.4 ± 2.3 21.4 ± 2.0
Viral Load (RNA copies/mL) 25740 ± 57300 277 ± 610 23186 ± 65878
CD4 cell count (cells/mm³) 435 ± 218 450 ± 190 429 ± 365
CD8 cell count (cells/mm³) 1076 ± 873 802 ± 328 1091 ± 528
Glucose (mg/dL) 84 ± 9 102 ± 33§ 79 ± 11**
Cholesterol (mg/dL)
Total 159 ± 27 180 ± 27 154 ± 34
HDL 39 ± 8 53 ± 16§ 38 ± 10*
LDL 100 ± 20 106 ± 19 97 ± 27
Triglycerides (mg/dL) 98 ± 33 103 ± 29 98 ± 37
PON1(nmol.min-1.mL-1) 45.7 ± 36.9 54.8 ± 42.9 33.5 ± 37.9
Lipid transfers (%)
Triglycerides 2.6 ± 0.8 3.1 ± 0.6§ 2.1 ± 0.3**
Free Cholesterol 5.0 ± 1.1 5.7 ± 1.0 4.3 ± 1.0**
Cholesteryl esters 2.9 ± 0.7 3.4 ± 0.6§ 2.8 ± 0.7*
Phospholipids 23.6 ± 1.6 23.8 ± 1.3 22.7 ± 1.6
BMI: Body Mass Index; PON1: paraoxonase 1. Results expressed as mean ± SD. *p < 0.05, **p < 0.01compared to NRTI with NNRTI (Kruskal-Wallis nonparametric
ANOVA test); § p < 0.05 compared to non-treated (Kruskal-Wallis nonparametric ANOVA test).
Table 1
Individual physical characteristics and plasma lipids
Parameters Controls HIV+ p
No. of subjects (M/F) 45 (16/29) 48 (22/26)
Age (years) 38 ± 9 37 ± 8 0.71
Weight (kg) 70.4 ± 14.8 63.6 ± 10.3 0.01
Height (m ) 1.64 ± 0.1 1.70 ± 0.1 0.09
BMI (kg/m2) 25.8 ± 3.7 22.7 ± 3.0 0.0001
Cholesterol (mg/dL)
Total 191 ± 33 164 ± 30 0.0001
HDL 41 ± 10 43 ± 13 0.44
LDL 127 ± 30 101 ± 21 < 0.0001
Triglycerides(mg/dL) 116 ± 39 99 ± 32 0.03
PON1 (nmol.min-1.mL-1) 71.8 ± 37.4 44.3 ± 38.6 0.001
BMI: Body Mass Index; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; PON1: paraoxonase 1. Results are expressed as mean ± SD, p < 0.05
(unpaired t-test).
Fig. 1 - Percentage of the labeled lipids transferred from the lipidic nanoemulsion to the
HDL fraction. Comparisons between HIV+ vs control groups: *p < 0.0001 (unpaired t-test).
Results are expressed as mean ± SD. FC = free cholesterol; PL = phoshpolipid; CE = cholesteryl
esters, TG = triglycerides
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different between non-treated and NRTI+NNRTI patients, but the CE
and TG transfer were greater in the NRTI+NNRTI than in the non-
treated group. However, when protease inhibitors were added to the
treatment, in the NRTI+PI group, HDL cholesterol diminished and all
the parameters of lipid transfer became altered, with the exception of
PL transfer.
DISCUSSION
In this study, the HIV+ group of patients showed LDL cholesterol
and triglyceride concentration in the plasma smaller than that of the
control HIV negative subjects, whereas HDL cholesterol was equal.
Indeed, HIV+ patients often show diminished LDL cholesterol10,25, but
triglycerides are generally described as increased in HIV+9,10, in contrast
with the results of this study. However, increased triglyceride
concentration leads to HDL cholesterol diminution5, and the fact that
triglycerides were not increased in our HIV+ group ultimately facilitates
the analysis of the HDL status.
The three subgroups of HIV+ patients did not differ among them in
respect to LDL cholesterol. HDL cholesterol, however, was greater in
the NRTI+NNRTI subgroup when compared with NRTI+PI, non-treated
HIV+ patients and also with the values of the HIV negative group. It
was also reported in other studies that treatment with NRTI+NNRTI
increases HDL cholesterol whereas addition of PI in the treatment
leads to decrease in this parameter4,26.
PON 1 activity that is associated with the ability of HDL to prevent
the accumulation of lipid peroxides on LDL and in the vessel wall19.
The diminution of PON 1 in HIV+ confirms the findings of PARRA et
al.24, both treated and non-treated patients.
The ability to receive lipids is a fundamental property of HDL.
HDL stabilizes the plasma cholesterol pool by promoting cholesterol
esterification, a process that is catalyzed by LCAT using apo A1, that
is mostly contained in the HDL fraction, as a co-factor. By producing
a completely apolar molecule, esterification of the cholesterol localized
in the particle surface monolayer results in shift of the compound to
the particle core, where it is isolated from the contact with the aqueous
medium. By receiving cholesterol from cells and other lipoproteins
and sending esterified cholesterol to other lipoprotein classes and to
hepatocytes for excretion in the bile, HDL plays is crucial role in the
reverse cholesterol transport16. Transfer of esterified cholesterol from
HDL to other lipoprotein classes is mediated by CETP. Reception of
phospholipids is also important for the HDL formation and remodeling
and triglycerides are also exchanged between triglyceride rich
lipoproteins such as VLDL and HDL30. This study shows that the ability
of HDL to receive lipids, a fundamental aspect of the metabolism of
this lipoprotein, is disturbed in HIV+ patients compared with the HIV
negative subjects. Those alterations, characterized by smaller transfer
of free cholesterol and triglycerides and increase in the transfer of
phospholipids from the lipid nanoparticles to HDL may cause or be
consequent of disturbances in the dynamics of the HDL metabolism
and the function of the lipoprotein in the plasma cholesterol stabilization
and reverse transport. On the other hand, compared to the HIV+ non-
treated patients, treatment with NRTI+NNRTI increased the transfer
to HDL of cholesteryl esters and triglyceride. In the group treated with
the NRTI+PI scheme, lipid transfer to HDL was unchanged. Those
differences in lipid transfer to HDL in response to different treatment
regimens are presumably related to the effect on lipid metabolism by
those drugs. In this respect, compared with NRTI+NNRTI, PI treatment
worsens the lipid profile4,20,26,31.
The disturbances of HDL metabolism in HIV+ found in this study
can be at least partially attributed to cytokine release consequent to
the infectious and inflammatory process. Those cytokines can diminish
HDL and modify the HDL composition and function, such as the anti-
oxidant properties of the lipoprotein11,24,32. Cytokine release in infectious
and inflammatory processes also results in diminished HDL uptake by
cells, by reducing the expression of ABCA1 system that helps in the
removal of free cholesterol from the cells to the HDL particles11. Those
changes may elicit alterations in the ability of HDL to receive lipids,
as observed in this study and in the shift of lipids from HDL to other
lipoproteins.
In conclusion, in the HIV+ population sample studied here PON1
activity and the ability of HDL to receive lipids were altered. This
suggests that functions of this uniquely protective lipoprotein can be
disturbed in those patients.
RESUMO
Alterações na transferência de lípides para a lipoproteína de alta
densidade (HDL) e atividade da paroxonase 1 em pacientes HIV+
Pacientes HIV+ freqüentemente desenvolvem alterações no
metabolismo de lípides que podem influir no desenvolvimento de
doença arterial coronária. A lipoproteína de alta densidade (HDL) tem
papel importante na prevenção da aterogênese. Para investigar aspectos
funcionais da HDL na doença, foram estudados 48 pacientes HIV+ e
45 indivíduos-controle saudáveis de ambos os sexos, com idade
semelhantes. Vinte e cinco pacientes HIV+ não recebiam terapia
antirretroviral, 13 estavam sob tratamento com inibidores nucleosídicos
de transcriptase reversa e não-nucleosídicos (NRTI+NNRTI) e 10 sob
tratamento com NRTI e inibidor de protease (NRTI+PI). Analisou-se a
atividade da paroxonase 1 e a transferência de colesterol livre e
esterificado, triglicérides e fosfolipídios de uma nanoemulsão lipídica
para a HDL. Pacientes HIV+ apresentaram menor atividade da
paroxonase 1 e menor transferência de colesterol livre e triglicérides
em relação aos indivíduos saudáveis. A transferência de fosfolipídios
foi maior nesses pacientes, mas a transferência de éster de colesterol
foi similar. NRTI+NNRTI aumenta a transferência de éster de colesterol
e triglicérides, mas em NRTI+PI não houve diferença comparando com
os pacientes HIV+ não tratados. A HDL de pacientes HIV+ tem
propriedades antioxidantes reduzidas, evidenciada pela menor atividade
da paraxonase 1, e transferência de lipídios alterada, sugerindo que a
HDL apresente função defeituosa nestes pacientes.
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